Technology

Xenetic

$2.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-9.33%) Today
+$0.27 (+11.11%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Xenetic and other stocks, options, and ETFs commission-free!

About XBIO

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA. The listed name for XBIO is Xenetic Biosciences, Inc. Common Stock.

CEO
Jeffrey F. Eisenberg
Employees
4
Headquarters
Framingham, Massachusetts
Founded
2011
Market Cap
19.62M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
857.13K
High Today
$2.67
Low Today
$2.42
Open Price
$2.62
Volume
367.70K
52 Week High
$5.85
52 Week Low
$0.44

Collections

XBIO Earnings

-$1.56
-$1.04
-$0.52
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 26, Pre-Market

You May Also Like

BEEMW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure